Vir tempts Astellas
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
Janux lets the genie out of the bottle
A more comprehensive dataset on JANX007 sends the group’s stock down.
ESMO 2025 – Novartis looks for Pluvicto prostate Addition
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.
GenFleet broadens its RAS ambitions
And Treeline and HengRui also get in on the pan-RAS act.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Novartis gets a PSMAfore green flag at last
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
